Interleukin-6-dependent phenotypic modulation of cardiac fibroblasts after acute myocardial infarction

Basic Research in Cardiology

Volumn 109, Issue 6, 2014, Pages

  Müller, Julia ^a   Gorressen, Simone ^a   Grandoch, Maria ^a   Feldmann, Kathrin ^a   Kretschmer, Inga ^a   Lehr, Stefan ^b   Ding, Zhaoping ^a   Schmitt, Joachim P ^a   Schrader, Jürgen ^a   Garbers, Christoph ^c   Heusch, Gerd ^d   Kelm, Malte ^a   Scheller, Jürgen ^a   Fischer, Jens W ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Extracellular matrix; Fibroblasts; Hyaluronan; Myocardial infarction; Remodeling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; HERMES ANTIGEN; HYALURONAN SYNTHASE 1; HYALURONAN SYNTHASE 2; HYALURONIC ACID; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SYNTHETASE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CARDIAC FIBROBLAST; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ASSAY; FIBROBLAST; HEART FUNCTION; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; MOLECULAR DYNAMICS; MOUSE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; EXTRACELLULAR MATRIX; GENETICS; HEART INFARCTION; PHYSIOLOGY;

ANIMALS; EXTRACELLULAR MATRIX; FIBROBLASTS; HYALURONIC ACID; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOFIBROBLASTS; PHENOTYPE;

EID: 84911889783     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-014-0440-y     Document Type: Article

References (39)

1. Ammirati E, Cannistraci CV, Cristell NA, Vecchio V, Palini AG, Tornvall P, Paganoni AM, Miendlarzewska EA, Sangalli LM, Monello A, Pernow J, Bjornstedt Bennermo M, Marenzi G, Hu D, Uren NG, Cianflone D, Ravasi T, Manfredi AA, Maseri A (2012) Identification and predictive value of interleukin-6+ interleukin-10+ and interleukin-6- interleukin-10+ cytokine patterns in ST-elevation acute myocardial infarction. Circ Res 111:1336–1348. doi:10.1161/CIRCRESAHA.111.262477
2. Anderson DR, Poterucha JT, Mikuls TR, Duryee MJ, Garvin RP, Klassen LW, Shurmur SW, Thiele GM (2013) IL-6 and its receptors in coronary artery disease and acute myocardial infarction. Cytokine 62:395–400. doi:10.1016/j.cyto.2013.03.020
3. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R (2008) The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 120:172–185. doi:10.1016/j.pharmthera.2008.08.002
4. Bonner F, Borg N, Burghoff S, Schrader J (2012) Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury. PLoS One 7:e34730. doi:10.1371/journal.pone.0034730
5. Buyukkaya E, Poyraz F, Karakas MF, Kurt M, Akcay AB, Akpinar I, Motor S, Turak O, Ozturk OH, Sen N, Akpek M, Kaya MG, Gibson CM (2013) Usefulness of monocyte chemoattractant protein-1 to predict no-reflow and three-year mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 112:187–193. doi:10.1016/j.amjcard.2013.03.011
6. Camenisch TD, Spicer AP, Brehm-Gibson T, Biesterfeldt J, Augustine ML, Calabro A Jr, Kubalak S, Klewer SE, McDonald JA (2000) Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest 106:349–360. doi:10.1172/JCI10272
7. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, Michael LH, Rollins BJ, Entman ML, Frangogiannis NG (2005) CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96:881–889. doi:10.1161/01.RES.0000163017.13772.3a
8. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG (2010) The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 48:504–511. doi:10.1016/j.yjmcc.2009.07.015
9. Empana JP, Jouven X, Canoui-Poitrine F, Luc G, Tafflet M, Haas B, Arveiler D, Ferrieres J, Ruidavets JB, Montaye M, Yarnell J, Morange P, Kee F, Evans A, Amouyel P, Ducimetiere P (2010) C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: the PRIME study. Arterioscler Thromb Vasc Biol 30:2047–2052. doi:10.1161/ATVBAHA.110.208785
10. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J, Rose-John S (1997) I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 15:142–145. doi:10.1038/nbt0297-142
11. Fuchs M, Hilfiker A, Kaminski K, Hilfiker-Kleiner D, Guener Z, Klein G, Podewski E, Schieffer B, Rose-John S, Drexler H (2003) Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J 17:2118–2120. doi:10.1096/fj.03-0331fje
12. Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M, Muller W, Scherr M, Theilmeier G, Ernst M, Hilfiker A, Drexler H (2010) Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 122:145–155. doi:10.1161/CIRCULATIONAHA.109.933127
13. Hoge J, Yan I, Janner N, Schumacher V, Chalaris A, Steinmetz OM, Engel DR, Scheller J, Rose-John S, Mittrucker HW (2013) IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J Immunol 190:703–711. doi:10.4049/jimmunol.1201044
14. Huebener P, Abou-Khamis T, Zymek P, Bujak M, Ying X, Chatila K, Haudek S, Thakker G, Frangogiannis NG (2008) CD44 is critically involved in infarct healing by regulating the inflammatory and fibrotic response. J Immunol 180:2625–2633
15. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S (2001) Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268:160–167
16. Kobara M, Noda K, Kitamura M, Okamoto A, Shiraishi T, Toba H, Matsubara H, Nakata T (2010) Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice. Cardiovasc Res 87:424–430. doi:10.1093/cvr/cvq078
17. Liehn EA, Merx MW, Postea O, Becher S, Djalali-Talab Y, Shagdarsuren E, Kelm M, Zernecke A, Weber C (2008) Ccr1 deficiency reduces inflammatory remodelling and preserves left ventricular function after myocardial infarction. J Cell Mol Med 12:496–506. doi:10.1111/j.1582-4934.2007.00194.x
18. Lindmark E, Diderholm E, Wallentin L, Siegbahn A (2001) Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 286:2107–2113
19. Lindner D, Zietsch C, Tank J, Sossalla S, Fluschnik N, Hinrichs S, Maier L, Poller W, Blankenberg S, Schultheiss HP, Tschope C, Westermann D (2014) Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Res Cardiol 109:428. doi:10.1007/s00395-014-0428-7
20. Malchow S, Thaiss W, Janner N, Waetzig GH, Gewiese-Rabsch J, Garbers C, Yamamoto K, Rose-John S, Scheller J (2011) Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling. Biochim Biophys Acta 1812:290–301. doi:10.1016/j.bbadis.2010.11.009
21. Melchior-Becker A, Dai G, Ding Z, Schafer L, Schrader J, Young MF, Fischer JW (2011) Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast phenotype. J Biol Chem 286:17365–17375. doi:10.1074/jbc.M110.192682
22. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL (2010) Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56:225–231. doi:10.1161/HYPERTENSIONAHA.109.148635
23. Merx MW, Gorressen S, van de Sandt AM, Cortese-Krott MM, Ohlig J, Stern M, Rassaf T, Godecke A, Gladwin MT, Kelm M (2014) Depletion of circulating blood NOS3 increases severity of myocardial infarction and left ventricular dysfunction. Basic Res Cardiol 109:398. doi:10.1007/s00395-013-0398-1
24. Midgley AC, Rogers M, Hallett MB, Clayton A, Bowen T, Phillips AO, Steadman R (2013) Transforming growth factor-beta1 (TGF-beta1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts. J Biol Chem 288:14824–14838. doi:10.1074/jbc.M113.451336
25. Nagy N, Freudenberger T, Melchior-Becker A, Rock K, Ter Braak M, Jastrow H, Kinzig M, Lucke S, Suvorava T, Kojda G, Weber AA, Sorgel F, Levkau B, Ergun S, Fischer JW (2010) Inhibition of hyaluronan synthesis accelerates murine atherosclerosis: novel insights into the role of hyaluronan synthesis. Circulation 122:2313–2322. doi:10.1161/CIRCULATIONAHA.110.972653
26. Negoro S, Kunisada K, Tone E, Funamoto M, Oh H, Kishimoto T, Yamauchi-Takihara K (2000) Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 47:797–805
27. Petrey AC, de la Motte CA (2014) Hyaluronan, a crucial regulator of inflammation. Front Immunol 5:101. doi:10.3389/fimmu.2014.00101
28. Rassaf T, Totzeck M, Hendgen-Cotta UB, Shiva S, Heusch G, Kelm M (2014) Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning. Circ Res 114:1601–1610. doi:10.1161/CIRCRESAHA.114.303822
29. Rock K, Meusch M, Fuchs N, Tigges J, Zipper P, Fritsche E, Krutmann J, Homey B, Reifenberger J, Fischer JW (2012) Estradiol protects dermal hyaluronan/versican matrix during photoaging by release of epidermal growth factor from keratinocytes. J Biol Chem 287:20056–20069. doi:10.1074/jbc.M112.353151
30. Savvatis K, Pappritz K, Becher PM, Lindner D, Zietsch C, Volk HD, Westermann D, Schultheiss HP, Tschope C (2014) Interleukin-23 deficiency leads to impaired wound healing and adverse prognosis after myocardial infarction. Circ Heart fail 7:161–171. doi:10.1161/CIRCHEARTFAILURE.113.000604
31. Scheller J, Garbers C, Rose-John S (2014) Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 26:2–12. doi:10.1016/j.smim.2013.11.002
32. Theroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB (2005) Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 26:1964–1970. doi:10.1093/eurheartj/ehi292
33. Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, Mao Z, Nevo E, Gorbunova V, Seluanov A (2013) High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 499:346–349. doi:10.1038/nature12234
34. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J (2010) Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 7:30–37. doi:10.1038/nrcardio.2009.199
35. Van Linthout S, Miteva K, Tschope C (2014) Crosstalk between fibroblasts and inflammatory cells. Cardiovasc Res 102:258–269. doi:10.1093/cvr/cvu062
36. Vernon RB, Gooden MD (2002) An improved method for the collagen gel contraction assay. In Vitro Cell Dev Biol Anim 38:97–101. doi:10.1290/1071-2690(2002)038<0097:AIMFTC>2.0.CO;2
37. Waetzig GH, Rose-John S (2012) Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets 16:225–236. doi:10.1517/14728222.2012.660307
38. Waldenstrom A, Martinussen HJ, Gerdin B, Hallgren R (1991) Accumulation of hyaluronan and tissue edema in experimental myocardial infarction. J Clin Invest 88:1622–1628. doi:10.1172/JCI115475
39. Westermann D, Mersmann J, Melchior A, Freudenberger T, Petrik C, Schaefer L, Lullmann-Rauch R, Lettau O, Jacoby C, Schrader J, Brand-Herrmann SM, Young MF, Schultheiss HP, Levkau B, Baba HA, Unger T, Zacharowski K, Tschope C, Fischer JW (2008) Biglycan is required for adaptive remodeling after myocardial infarction. Circulation 117:1269–1276. doi:10.1161/CIRCULATIONAHA.107.714147